| Date | Title | | | 11/22/11 | SurModics to Attend Piper Jaffray's 23rd Annual Health Care Conference on November 29| EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Nov. 22, 2011--
SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface
modification technologies to the healthcare industry, announced today
that it will participate in Piper Jaffray’s 23rd Annual
Healthcare Conference in New York City on Tuesday, November 29, 2011.
Gary Maharaj, SurModics’ President and Chief Executive Officer, and
Timothy Arens, Vice President of Finance and interim Chief Financial
... |
|  | | 11/17/11 | SurModics Completes Sale of Pharmaceutical Assets| EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Nov. 17, 2011--
SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface
modification technologies to the healthcare industry, announced today
that it has completed the previously-announced sale of its SurModics
Pharmaceuticals assets to Evonik Industries AG (“Evonik”).
Under the terms of the sale, the entire portfolio of products and
services of SurModics Pharmaceuticals, including the Company’s cGM... |
| | | 11/03/11 | SurModics Reports Fourth Quarter and Fiscal Year 2011 Results| Sequential Revenue Growth in Core Businesses
Achieved 2011 Non-GAAP Guidance
EDEN PRAIRIE, Minn., Nov 03, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for the fourth quarter and fiscal year ended September 30, 2011.
Fourth Quarter Summary:
GAAP results:
Revenue of $17.2 million
Asset impairment charge, associated with SurModics Pharmac... |
| | | 11/02/11 | SurModics to Webcast Fourth Quarter and Fiscal Year 2011 Earnings Conference Call November 3| EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--
SurModics, Inc. (Nasdaq:SRDX - News), a leading provider of surface
modification technologies to the healthcare industry, announced today
that it will host a live webcast of its fourth quarter and fiscal year
2011 conference call on Thursday, November 3, at 4:00 p.m. CT. The
Company will issue an earnings news release after the market closes that
afternoon.
Gary Maharaj, chief executive office... |
| | | 11/01/11 | SurModics Announces Agreement to Sell Pharmaceutical Assets| Achieves Important Milestone towards Returning Company to
Sustainable, Long-Term Profitability
Enhances Strategic Focus on Core Medical Device and IVD Businesses
Creates Compelling Value for All Stakeholders
EDEN PRAIRIE, Minn., Nov 01, 2011 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface
modification technologies to the healthcare industry, announced today
that it has entered into a definitive agreement to sell its SurModics
P... |
| | | 09/20/11 | SurModics IVD Introduces A New BioFX(R) TMB
Enhanced HRP Membrane Substrate| A Winner of the LifeScience Alley(R) 2011 New
Technology Showcase!
EDEN PRAIRIE, Minn., Sep 20, 2011 (BUSINESS WIRE) --SurModics IVD introduces BioFX(R) TMB Enhanced HRP Membrane
Substrate. SurModics IVD, a wholly owned subsidiary of SurModics, Inc.
(Nasdaq: SRDX), is a market leader for immunoassay reagents for
diagnostic test kits used to detect absence or presence of disease.
BioFX TMB Enhanced HRP Membrane Substrate (ESPM) is the latest
additio... |
| | | 09/13/11 | SurModics to Attend CL King's 9th Annual
Best Ideas Conference on September 14| EDEN PRAIRIE, Minn., Sep 12, 2011 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and
surface modification technologies to the healthcare industry, announced
today that it will participate in CL King's 9th Annual Best
Ideas Conference in New York City on Wednesday, September 14, 2011. Gary
Maharaj, SurModics' President and Chief Executive Officer, and Timothy
Arens, Vice President of Finance and interim Chief Financial... |
| | | 08/23/11 | SurModics Announces Strategic Realignment of Business| - Align cost structure and leadership team to its strategic plan -
- Maintain commitment to R&D, core Medical Device and IVD businesses -
EDEN PRAIRIE, Minn., Aug 23, 2011 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and
surface modification technologies to the healthcare industry, announced
today a realignment of its business to optimize Company resources
according to its strategic plan.
As part of the strategic reali... |
| | | 08/03/11 | SurModics Reports Third Quarter 2011 Results| Raising Earnings Guidance for Full Year Fiscal 2011
EDEN PRAIRIE, Minn., Aug 03, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for the third quarter ended June 30, 2011.
Third Quarter Summary:
GAAP results:
Revenue of $18.0 million, up 3% sequentially
Operating income of $3.4 million
Net income of $3.8 million
Diluted EPS of $0.22
... |
| | | 07/28/11 | SurModics to Webcast Third Quarter Fiscal Year 2011 Earnings
Conference Call August 3| Webcast is Live at 4:00 p.m. (CT)
EDEN PRAIRIE, Minn., Jul 28, 2011 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and
surface modification technologies to the healthcare industry, announced
today that it will host a live webcast of its third quarter 2011
conference call on Wednesday, August 3, at 4:00 p.m. CT. The Company
will issue an earnings news release after the market closes that
afternoon.
Gary Maharaj... |
| | | 07/26/11 | SurModics Introduces New In Vitro Diagnostics Product -
SurModics(R) Assay Diluent (Protein-Free)| EDEN PRAIRIE, Minn., Jul 26, 2011 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and
surface modification technologies to the healthcare industry, will
introduce its SurModics(R) Assay Diluent (Protein-Free) product at the
American Association for Clinical Chemistry (AACC) - Clinical Lab Expo,
July 26-28, 2011 in Atlanta, GA (booth #1302).
The SurModics Assay Diluent is a proprietary, protein-free, buffer
formula... |
| | | 06/15/11 | SurModics Comments on Johnson & Johnson Announcement| SurModics re-affirms fiscal 2011 guidance
EDEN PRAIRIE, Minn., Jun 15, 2011 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and
surface modification technologies to the healthcare industry, responded
to Johnson & Johnson's announcement earlier today that Cordis
Corporation, a J&J company, will stop the manufacture of CYPHER(R) and
CYPHER SELECT(R) Plus Sirolimus-Eluting Coronary Stents by the end of 2011.
Gary ... |
| | | 04/27/11 | SurModics Reports Second Quarter 2011 Results| Sequential Revenue Growth in All Three Business Units; Raising Guidance for Full Year Fiscal 2011
EDEN PRAIRIE, Minn., Apr 27, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for the second quarter ended March 31, 2011.
Second Quarter Summary:
GAAP results:
Revenue of $17.5 million, up 15% sequentially
Operating income of $2.0 million
Ne... |
| | | 04/20/11 | SurModics to Webcast Second Quarter Fiscal Year 2011 Earnings
Conference Call April 27| Webcast is Live at 4:00 p.m. (CT)
EDEN PRAIRIE, Minn., Apr 20, 2011 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and
surface modification technologies to the healthcare industry, announced
today that it will host a live webcast of its second quarter 2011
conference call on Wednesday, April 27, at 4:00 p.m. CT. The Company
will issue an earnings news release after the market closes that
afternoon.
Gary Mahara... |
| | | 02/03/11 | SurModics to Webcast Annual Meeting on February 7| EDEN PRAIRIE, Minn., Feb 03, 2011 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and
surface modification technologies to the healthcare industry, announced
today that it will host a live webcast of its Annual Meeting of
Shareholders on Monday, February 7, at 4:00 p.m. CT.
Gary Maharaj, president and chief executive officer, Phil Ankeny, senior
vice president and chief financial officer, and Bob Buhrmaster, chairman
... |
| | | 01/26/11 | SurModics Reports First Quarter 2011 Results| EDEN PRAIRIE, Minn., Jan 26, 2011 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for the first quarter ended December 31, 2010.
First Quarter Summary:
GAAP results:
Revenue of $15.2 million, down 2% sequentially
Restructuring charges of $1.2 million
Goodwill impairment charge of $0.8 million
Operating loss of $0.7 million
Net loss of $0.4 m... |
| | | 01/19/11 | SurModics to Webcast First Quarter Fiscal Year 2011 Earnings
Conference Call January 26| Webcast is Live at 4:00 p.m. (CT)
EDEN PRAIRIE, Minn., Jan 19, 2011 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and
surface modification technologies to the healthcare industry, announced
today that it will host a live webcast of its first quarter 2011
conference call on Wednesday, January 26, at 4:00 p.m. CT. The Company
will issue an earnings news release after the market closes that
afternoon.
Gary Mahar... |
| | | 01/05/11 | SurModics and Ramius Reach Agreement Regarding 2011 Annual Meeting of
Shareholders | Jeffrey C. Smith and David Dantzker, M.D. Appointed to SurModics'
Board of Directors;
Board Forms Special Committee to Oversee Previously Announced Review
of Strategic Alternatives for Pharmaceuticals Business;
Ramius Agrees to Support SurModics Director Nominees at 2011 Annual
Meeting of Shareholders
EDEN PRAIRIE, Minn., Jan 05, 2011 (BUSINESS WIRE) --SurModics, Inc. (Nasdaq: SRDX) ("the Company"), a leading provider of
drug delivery and surface modificati... |
| |
|
